Markers for Melanoma Progression
Author Information
Author(s): Boyano M D, Garcia-Vázquez M D, López-Michelena T, Gardeazabal J, Bilbao J, Cañavate M L, Galdeano A García De, Izu R, Díaz-Ramón L, Raton J A, Díaz-Pérez J L
Primary Institution: Department of Cell Biology and Morphological Sciences, School of Medicine and Dentistry, University of the Basque Country
Hypothesis
The study aims to evaluate the clinical relevance of serum levels of sIL-2R, sICAM-1, and IL-10 in patients with melanoma.
Conclusion
Higher serum levels of sIL-2R, sICAM-1, and detectable IL-10 levels are associated with poorer prognosis in melanoma patients.
Supporting Evidence
- Mean values of sIL-2R were significantly higher than in normal controls in all stages of melanoma.
- Patients with sIL-2R levels > 529 U/ml had a significantly poorer prognosis.
- Levels of sICAM-1 were elevated in melanoma patients, especially during metastatic disease.
- Detectable IL-10 levels were more frequent in patients who developed metastasis.
Takeaway
Doctors looked at certain markers in the blood of melanoma patients to see if they could tell how serious the disease was. They found that higher levels of these markers meant a worse outcome for the patients.
Methodology
A longitudinal study with a 3-year follow-up analyzing serum levels of specific markers in melanoma patients.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website